Evaluation of the Metabolic Activity of Echinococcus multilocularis in Rodents Using Positron Emission Tomography Tracers
Evaluation of the Metabolic Activity of Echinococcus multilocularis in Rodents Using Positron Emission Tomography Tracers
复制标题
DOI：
10.1007/s11307-014-0815-3
复制
发表时间：
2015-08-01
影响因子：
3.1
通讯作者：
Wiehr, Stefan
中科院分区：
文献类型：
--
作者：
Rolle, Anna-Maria;Soboslay, Peter T.;Wiehr, Stefan
2-脱氧-2-[F-18]氟-d-葡萄糖（[F-18]FDG）已被用作临床标准的正电子发射断层扫描（PET）示踪剂，用于罕见但危及生命的寄生虫病肺泡棘球蚴病（AE）的随访。鉴于该疾病在北半球许多国家流行，诊断仍然具有挑战性，我们研究的目的是进一步评估临床相关的PET示踪剂作为AE体外和体内可能的诊断工具。各种临床使用的PET示踪剂在体外进行了评估，并在基于PET/磁共振（MR）测量的AE动物模型中进行了评估。体外结合实验显示，[F-18]FDG在多房棘球绦虫组织的细胞悬浮液中被高度吸收，而3'-脱氧-3'-[F-18]氟胸苷（[F-18]FLT）和[C-11]胆碱被发现被多房棘球绦虫囊泡强烈吸收。[F-18]FDG和[F-18]FLT在体内表现出较高的摄取，在整个寄生虫组织中表现为多个灶，而[F-18]氟-azomycinarabinofuranoside （[F-18]FAZA）和[C-11]胆碱则相反。我们的数据清楚地表明，临床应用的PET示踪剂[F-18]FDG对AE的诊断和疾病分期有用，但在评估目前不活跃或代谢弱的寄生虫病变方面也存在缺陷。不同测试的PET示踪剂没有显示出替代或补充当前诊断策略的潜力。因此，仍然需要新的诊断工具。
2-Deoxy-2-[F-18]fluoro-d-glucose ([F-18]FDG) has been used as a standard clinical positron emission tomography (PET) tracer for the follow-up of the rare but life-threatening parasitic disease alveolar echinococcosis (AE). Given that the disease is endemic in many countries in the northern hemisphere and the diagnosis is still challenging, the aim of our study was to evaluate further clinically relevant PET tracers as possible diagnostic tools for AE in vitro and in vivo.Various clinically used PET tracers were evaluated in vitro and assessed in an in vivo AE animal model based on PET/magnetic resonance (MR) measurements.In vitro binding assays displayed high uptake of [F-18]FDG in a cell suspension of E. multilocularis tissue, whereas 3'-deoxy-3'-[F-18]fluorothymidine ([F-18]FLT) and [C-11]choline were found to be taken up strongly by E. multilocularis vesicles. [F-18]FDG and [F-18]FLT displayed an elevated uptake in vivo, which appeared as several foci throughout the parasite tissue as opposed to [F-18]fluoro-azomycinarabinofuranoside ([F-18]FAZA) and [C-11]choline.Our data clearly demonstrate that the clinically applied PET tracer [F-18]FDG is useful for the diagnosis and disease staging of AE but also has drawbacks in the assessment of currently inactive or metabolically weak parasitic lesions. The different tested PET tracers do not show the potential for the replacement or supplementation of current diagnostic strategies. Hence, there is still the need for novel diagnostic tools.